Celltrion Healthcare showcases initial data from year-long study for subcutaneous formulation of CT-P13 (biosimilar infliximab) in patients with Crohn’s disease
New data presented at the 14th congress of European Crohn’s and Colitis Organisation (ECCO) show that the subcutaneous (SC) formulation of CT-P13 is comparable in terms of efficacy and safety with the intravenous (IV) formulation of CT-P13 for the treatment of patients with Crohn’s Disease (CD) up to week 54.1
The randomised, controlled phase I study evaluated efficacy, pharmacokinetic (PK) parameters and the overall safety profile of CT-P13 SC throughout the 1-year treatment period.
In the study, 44 patients with moderate to severe CD were randomly assigned into four cohorts; one group receiving CT-P13 IV 5mg/kg every 8weeks and the other three receiving different doses of CT-P13 SC (120mg/180mg/240mg) bi-weekly up to week 54. From week 6 to week 30, the results showed comparable overall clinical response of CT-P13 SC to CT-P13 IV with similar CDAI-70 scores, whereas clinical remission appears to be numerically higher in the SC cohorts at week 54. The safety profiles of CT-P13 in the SC cohorts were comparable to CT-P13 IV up to week 54.1
Celltrion also presented PK and overall safety profile data for two administration methods for CT-P13 SC - auto-injection (AI) and pre-filled syringe (PFS). As part of the study, 218 healthy subjects were randomly split into two groups to receive 120mg of CT-P13 SC via AI or PFS for 12 weeks. The results showed a similar PK and safety profile between CT-P13 SC being administered via AI and PFS, however the study showed administration via AI led to fewer injection site reactions and reduced pain.2 AI also has the potential benefit of being simpler to self-administer and reducing patient distress compared to administration via PFS, meaning that this could be a preferable administration option for CT-P13 SC.
Professor Walter Reinisch, Director of clinical IBD study group, Department of Gastroenterology and Hepatology, Medizinische Universität Wien said, “The year-long results show a comparable PK, efficacy and safety profile between CT-P13 SC and IV. This data is encouraging in showing that CT-P13 SC is safe and efficacious as a treatment for Crohn’s disease and the SC formulation has the potential to be used as an alternative infliximab treatment in the future. CT-P13 SC could become a game-changer in biosimilar treatment by improving convenience and allowing patients to be more in control of their treatment.”
Mr. Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare said, “The availability of a subcutaneous version of CT-P13 will be an important milestone for our biosimilars portfolio, expanding the range of treatment options for the millions of patients living with chronic inflammatory diseases such as Crohn’s disease. We are committed to providing physicians with treatment options that suit the individual needs and preferences of their patients, whether that is intravenous or subcutaneous. If CT-P13 SC is approved in Europe, the dual formulation of infliximab could offer patients a more convenient treatment option.”
Notes to editors:
About inflammatory bowel disease
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disabling gastrointestinal disorders that impact every aspect of a patient’s life.3 They affect an estimated 5 million people globally.4 IBD accounts for substantial costs to the healthcare system and society; the direct healthcare costs of IBD is estimated to be €4.6-5.6 billion per year.5
About CT-P13 (biosimilar infliximab)
CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 89 countries (as of Nov 2018) including the US, Canada, Japan and throughout Europe.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/
1 Reinisch W, et al. A novel formulation of CT-P13
(infliximab biosimilar) for subcutaneous administration: 1-year result
from a phase 1 open-label randomised controlled trial in patients with
active Crohn’s disease. European Crohn’s and Colitis Organisation 2019.
Abstract no: A-1103.
2 Schreiber S, et al. Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase 1 randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects. European Crohn’s and Colitis Organisation 2019. Abstract no: A-1165.
3 Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1)46–54.
4 The European Federation of Crohn’s & Ulcerative Colitis Associations. What is IBD? Science. Available at: http://www.efcca.org/en/science.
5 Burisch J, et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis (2013)7,322-337.
ABSTRACT NUMBER: A-1103
DATE AND TIME OF PRESENTATION:
March 8th, 17:47 – 17:53 CET
ABSTRACT NUMBER: A-1165
DATE AND TIME OF PRESENTATION:
March 8th, 12:30 CET
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Results Are In! BOC Group Named a Leader in the Enterprise Architecture Management Suites, Q1 2019 report by Independent Research Firm25.3.2019 13:32:00 CET | Pressemelding
BOC Group, the leading global provider of Enterprise Management Solutions, announced today that it has been recognized as a “Leader” in The Forrester Wave™: Enterprise Architecture Management Suites, Q1 2019 report. Evaluated against 35 rigorous criteria, BOC Group’s EA suite ADOIT received the highest possible scores in 16 of them, including customer satisfaction, innovation agenda criteria and many others! Christoph Moser, ADOIT product manager, comments on this accomplishment by saying: “We see this achievement as an affirmation of our unwavering position as a front-runner in the EA industry and a direct reflection of the strength, depth and breadth we have incorporated across all aspects of our comprehensive, user-centric EA offering and portfolio in the last years.” Moser continues: “For us, this recognition is hard-earned and well deserved. But more importantly, we believe it further proves our strategy, relentless commitment to our customers, and continued mission to enable orga
ResMed Launches Next-generation ReSupply Solution25.3.2019 13:00:00 CET | Pressemelding
ResMed (NYSE: RMD) (ASX: RMD) today launched its automated ResMed ReSupply solution for all U.S. home medical equipment (HME) providers to increase sleep apnea patients’ long-term therapy adherence and improve patient satisfaction. Patients enrolled in an automated resupply program are 50 percent less likely to stop PAP (positive airway pressure) therapy within the first year, according to a 2018 study. ResMed’s program goes one step further, automating enrollment as patients meet compliance requirements and letting patients choose their preferred contact method – text, email or live call. Patients can also order supplies through a web- or mobile-based patient portal. HMEs are able to manage all their patients’ resupply needs from a single comprehensive dashboard so they can quickly identify, prioritize and assign tasks. “The new resupply platform is simple and easy to use – everything you need is at your fingertips,” said Kera Tennyson, a PAP location manager at Advanced Medical Solut
Sigma Systems Named Finalist for 4 Industry Awards25.3.2019 12:00:00 CET | Pressemelding
Sigma Systems, the global leader in catalog-driven software, today announced that it has been named as a finalist for two TM Forum Excellence Awards and as a semi-finalist for two Pipeline Innovation Awards. The TM Forum’s Excellence Awards highlight companies and individuals that demonstrate commitment to the evolution of the industry through digital transformation and the adoption of best practices and standards that TM Forum delivers through its Collaboration Community. Sigma is a finalist in the Service Innovator of the year and Catherine Michel is a finalist for the CTO of the Year – an award that she won in 2018. Nik Willetts, CEO, TM Forum said “Congratulations to the finalists of the TM Forum Excellence Awards 2019. As ever, the quality of the competition this year was incredibly high. With 5G fast approaching and pressure to digitally transform intensifying, it’s great to see these organizations pave the way for change and transformation. We’re excited and proud to work alongs
Newmont Announces Conditional Special Dividend25.3.2019 11:55:00 CET | Pressemelding
Newmont Mining Corporation (NYSE: NEM) (Newmont or the Company) today announced that its Board of Directors declared a one-time special dividend of $0.88 per share of common stock, conditional upon approval of the Goldcorp Inc. (NYSE: GG) (TSX: G) (Goldcorp) transaction. The dividend will be paid to Newmont shareholders of record as of April 17, 2019 (the record date), which is prior to closing of the proposed Newmont Goldcorp combination. The special dividend is conditional upon the approval by both Newmont’s and Goldcorp’s shareholders of the resolutions to be considered at their shareholder meetings on April 11 and April 4, 2019, respectively, in connection with the proposed transaction. The special dividend will be paid, subject to satisfaction of the conditions, on May 1, 2019. Closing of the Newmont Goldcorp transaction is expected shortly after the two shareholder special meetings if shareholders of both companies approve the resolutions. The special dividend delivers value to e
Tradeweb Markets Commences Roadshow for Initial Public Offering25.3.2019 11:30:00 CET | Pressemelding
Tradeweb Markets, a leading, global operator of electronic marketplaces for rates, credit, equities and money markets, today announced that it has commenced the roadshow for the initial public offering of its Class A common stock. Tradeweb Markets is offering 27,268,767 shares of its Class A common stock at an initial public offering price between $24.00 and $26.00 per share. Tradeweb Markets expects to grant the underwriters a 30-day option to purchase up to an additional 4,090,315 shares of Class A common stock at the initial public offering price, less the underwriting discounts and commissions. The shares are expected to trade on the NASDAQ Global Select Market under the ticker symbol "TW." Tradeweb intends to use the net proceeds from the offering to purchase equity interests from certain existing bank stockholders. Refinitiv will continue to own a controlling interest in Tradeweb following the offering. J.P. Morgan, Citigroup, Goldman Sachs & Co. LLC and Morgan Stanley are acting
GeoSpock and X-Locations Collaborate to Deliver Next Generation Location Data Analysis in Japan25.3.2019 11:00:00 CET | Pressemelding
GeoSpock® – the extreme-scale spatial big data integration company that provides analytics, builds insight, and enables predictions across space and time – today announced a new partnership with X-Locations – the Japan-based location AI platform company. The companies will be collaborating on a series of projects in Japan to raise awareness of the importance of location intelligence, as well as to demonstrate how and why we should be leveraging this data. The partnership will see X-Locations integrate GeoSpock’s unique spatial big data platform – which offers extreme geospatial scale and the hyper-efficient retrieval of data – into their products to improve speed of query, increase scale capacity, and reduce cost. Through the utilisation of artificial intelligence (AI) and machine learning, X-Locations accelerates the analysis and visualisation of big spatial data, enabling clients to make smarter decisions across multiple industries, including retail, real estate, manufacturing, and f